lisocabtagene maraleucel,ibrutinib,venetoclax,obinutuzumab
BMS,Roche,Abbvie
['obinu', 'venetoclax']
median 5 prior lines
70% btki+bcl2i refractory
89% received bridging therapy (venetoclax (44%) &amp; obinutuzumab (28%))
21 patients not efficacy evaluable (?haven't had response assessment yet?)
#asco23 
haematology registrar | @harvardmed fellow @PORTAL_research | evidence-based medicine & policy | lymphoma | myeloma | Fulbright | writer | SoMe Ed @BrJHaem